Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

Published:2021-05-18 Issue:5 Volume:128 Page:607-614
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Ravi Praful¹^ORCID,Pond Gregory R.²,Diamantopoulos Leonidas N.³⁴,Su Christopher⁵,Alva Ajjai⁵,Jain Rohit K.⁶,Skelton William P.⁶^ORCID,Gupta Sumati⁷,Tward Jonathan D.⁷,Olson Kathleen M.⁸,Singh Parminder⁸,Grunewald Camilla M.⁹,Niegisch Guenter⁹,Lee Jae‐Lyun¹⁰,Gallina Andrea¹¹,Bandini Marco¹¹^ORCID,Necchi Andrea¹²^ORCID,Mossanen Matthew¹¹³^ORCID,McGregor Bradley A.¹,Curran Catherine¹,Grivas Petros³,Sonpavde Guru P.¹

Affiliation:

1. Dana‐Farber Cancer Institute Boston MA USA

2. McMaster University Hamilton ON Canada

3. Fred Hutchinson Cancer Research Center Seattle University of Washington Seattle WAUSA

4. University of Pittsburg Medical Center Pittsburgh PAUSA

5. University of Michigan Ann Arbor MIUSA

6. Moffitt Cancer Center Tampa FLUSA

7. University of Utah's Huntsman Cancer Institute Salt Lake City UTUSA

8. Mayo Clinic College of Medicine Scottsdale AZ USA

9. Department of Urology Medical Faculty Heinrich‐Heine‐University Düsseldorf Düsseldorf Germany

10. Asan Medical Center University of Ulsan College of Medicine Seoul Korea

11. Vita‐Salute San Raffaele University MilanItaly

12. Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

13. Brigham and Women's Hospital Boston MA USA

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15434

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

3. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data

4. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

5. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis;Frontiers in Immunology;2024-01-09

2. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group;Journal of Clinical Oncology;2023-12-10

3. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis;BMC Cancer;2023-11-06

4. Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study;Clinical Genitourinary Cancer;2023-08

5. Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study;Cancer Medicine;2023-04-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3